المؤلفون: S. A. Avdeev, Z. R. Aisanov, V. V. Arkhipov, A. S. Belevskiy, I. V. Leshchenko, A. I. Sinopal’nikov, С. Н. Авдеев, З. Р. Айсанов, В. В. Архипов, А. С. Белевский, И. В. Лещенко, А. И. Синопальников

المساهمون: This publication is supported by Boehringer Ingelheim LLC company. The company is not responsible for the content of this article. The author's and the editorial's opinions could differ from the position of the Boehringer Ingelheim LLC company., Статья опубликована при финансовой поддержке ООО Берингер Ингельхайм. ООО Берингер Ингельхайм не несет ответственности за содержание статьи. Мнение ООО Берингер Ингельхайм может отличаться от мнения авторов статьи и редакции.

المصدر: PULMONOLOGIYA; Том 29, № 5 (2019); 632-636 ; Пульмонология; Том 29, № 5 (2019); 632-636 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2019-29-5

مصطلحات موضوعية: алгоритм отмены ингаляционных глюкокортикостероидов, inhales corticosteroids, ICS withdrawal, long-acting bronchodilators, therapeutic algorithm, ингаляционные глюкокортикостероиды, отмена ингаляционных глюкокортикостероидов, бронходилататоры длительного действия, алгоритм терапии хронической обструктивной болезни легких

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/1234/959; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. 2019 Report. Available at: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf; Adeloye D., Chua S., Lee C. et al. Global and regional estimates of COPD prevalence: Systematic review and metaanalysis. J. Glob. Health. 2015; 5 (2): 020415. DOI:10.7189/jogh.05-020415.; Global Burden of Disease 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385 (9963): 117–171. DOI:10.1016/S0140-6736(14)61682-2.; Lopez A.D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006; 27 (2): 397–412. DOI:10.1183/09031936.06.00025805.; World Health Organization. Projections of mortality and causes of death, 2015 and 2030. Available at: https://www.who.int/healthinfo/global_burden_disease/projections2015_2030/en/; Nannini L.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (9): CD006829. DOI:10.1002/14651858.CD006829.pub2.; Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178 (4): 332–338. DOI:10.1164/rccm.200712-1869OC.; Gershon A.S., Campitelli M.A., Croxford R. et al. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014; 312 (11): 1114–1121. DOI:10.1001/jama.2014.11432.; Ferguson G.T., Calverley P.M., Anderson J.A. et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009; 136 (6): 1456–1465. DOI:10.1378/chest.08-3016.; Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011; 66 (8): 699–708. DOI:10.1136/thx.2011.160028.; Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123 (11): 1001–1006. DOI:10.1016/j.amjmed.2010.06.019.; Wang J.J., Rochtchina E., Tan A.G. et al. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009; 116 (4): 652–657. DOI:10.1016/j.ophtha.2008.12.001.; Andrejak C., Nielsen R., Thomsen V.O. et al. Chronic respiratory disease, inhaled corticosteroids and risk of nontuberculous mycobacteriosis. Thorax. 2013; 68 (3): 256–262. DOI:10.1136/thoraxjnl-2012-201772.; Dong Y.H., Chang C.H., Wu F.L. et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and inf luenza: A systematic review and meta-analysis of randomized controlled trials. Chest. 2014; 145 (6): 1286–1297. DOI:10.1378/chest.13-2137.; Lee C.H., Kim K., Hyun M.K. et al. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013; 68 (12): 1105–1113. DOI:10.1136/thoraxjnl-2012-203175.; Price D., Yawn B., Brusselle G., Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 2013; 22 (1): 92–100. DOI:10.4104/pcrj.2012.00092.; https://journal.pulmonology.ru/pulm/article/view/1234

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/1234
https://doi.org/10.18093/0869-0189-2019-29-5-632-636

المؤلفون: S. N. Avdeev, Z. R. Aisanov, V. V. Arkhipov, A. S. Belevskiy, I. V. Leshchenko, S. I. Ovcharenko, E. I. Shmelev, M. Miravitls, С. Н. Авдеев, З. Р. Айсанов, В. В. Архипов, А. С. Белевский, И. В. Лещенко, С. И. Овчаренко, Е. И. Шмелев, М. Mиравитлс

المساهمون: Статья опубликована при финансовой поддержке ООО «Берин - гер Ингельхайм». ООО «Берингер Ингельхайм» не несет ответственности за содержание статьи. Мнение ООО «Берингер Ингельхайм» может отличаться от мнения авторов статьи и редакции

المصدر: PULMONOLOGIYA; Том 29, № 3 (2019); 334-345 ; Пульмонология; Том 29, № 3 (2019); 334-345 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2019-29-3

مصطلحات موضوعية: алгоритм отмены ингаляционных глюкокортикостероидов, inhaled drugs, inhaled corticosteroids, withdrawal of inhaled corticosteroids, long-acting bronchodilators, ICS withdrawal algorithm, ингаляционные препараты, ингаляционные глюкокортикостероиды, отмена ингаляционных глюкокортикостероидов, бронходилататоры длительного действия

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/1177/927; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD. 2019 GOLD Reports. Available at: https://goldcopd.org/gold-reports/ (Accessed: December 11, 2018).; Barnes P.J. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin. Chest Med. 2014; 35 (1): 71–86. DOI:10.1016/j.ccm.2013.10.004.; Cataldo D., Derom E., Liistro G. et al. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 2089–2099. DOI:10.2147/COPD.S164259.; Nannini L.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (9): CD006829. DOI:10.1002/14651858.CD006829.pub2.; Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178 (4): 332–338. DOI:10.1164/rccm.200712-1869OC.; Gershon A.S., Campitelli M.A., Croxford R. et al. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014; 312 (11): 1114–1121. DOI:10.1001/jama.2014.11432.; Lee J.H., Lee Y.K., Kim E.K. et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir. Med. 2010; 104 (4): 542–549. DOI:10.1016/j.rmed.2009.10.024.; Agusti A., Bel E., Thomas M. et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur. Respir. J. 2016; 47 (2): 410–419. DOI:10.1183/13993003.01359-2015.; Dicker A.J., Crichton M.L., Pumphrey E.G. et al. Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2018; 141 (1): 117–127. DOI:10.1016/j.jaci.2017.04.022.; Contoli M., Pauletti A., Rossi M.R. et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur. Respir. J. 2017; 50 (4): pii 1700451. DOI:10.1183/13993003.00451-2017.; Chalmers J.D. POINT: Should an attempt be made to withdraw inhaled corticosteroids in all patients with stable GOLD 3 (30% ≤ FEV1 < 50% predicted) COPD? Yes. Chest. 2018; 153 (4): 778–782. DOI:10.1016/j.chest.2018.01.029.; Yawn B.P., Li Y., Tian H. et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 295–304. DOI:10.2147/COPD.S42366.; Arkhipov V., Arkhipova D., Miravitlles M. et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 3255–3262. DOI:10.2147/COPD.S142997.; Price D., Yawn B., Brusselle G., Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 2013; 22 (1): 92–100. DOI:10.4104/pcrj.2012.00092.; Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999; 340 (25): 1948–1953. DOI:10.1056/NEJM199906243402503.; Burge P.S., Calverley P.M, Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320 (7245): 1297–1303. DOI:10.1136/bmj.320.7245.1297.; Jones P.W., Willits L.R., Burge P.S., Calverley P.M. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur. Respir. J. 2003; 21 (1): 68–73. DOI:10.1183/09031936.03.00013303.; Zervas E., Samitas K., Gaga M. et al. Inhaled corticosteroids in COPD: pros and cons. Curr. Drug Targets. 2013; 14 (2): 192–224. DOI:10.2174/1389450111314020006.; Cheng S.L., Su K.C., Wang H.C. et al. Chronic obstructive pulmonary disease treated with inhaled medium- or highdose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. Drug Des. Devel. Ther. 2014; 8: 601–607. DOI:10.2147/DDDT.S63100.; Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789. DOI:10.1056/NEJMoa063070.; Vestbo J., Anderson J.A., Brook R.D. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016; 387 (10030): 1817–1826. DOI:10.1016/S0140-6736(16)30069-1.; Rossi A., van der Molen T., del Olmo R. et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur. Respir. J. 2014; 44 (6): 1548–1556. DOI:10.1183/09031936.00126814.; Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21 (1): 74–81. DOI:10.1183/09031936.03.00031402.; Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22 (6): 912–919. DOI:10.1183/09031936.03.00027003.; Rodrigo G.J., Castro-Rodriguez J.A., Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest. 2009; 136 (4): 1029–1038. DOI:10.1378/chest.09-0821.; Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26. DOI:10.1164/rccm.200707-973OC.; Barnes P.J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2013; 131 (3): 636–645. DOI:10.1016/j.jaci.2012.12.1564.; Pascoe S., Locantore N., Dransfield M.T. et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3 (6): 435–442. DOI:10.1016/S2213-2600(15)00106-X.; Siddiqui S.H., Guasconi A., Vestbo J. et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 192 (4): 523–525. DOI:10.1164/rccm.201502-0235LE.; Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI:10.1056/NEJMoa1516385.; Roche N., Chapman K.R., Vogelmeier C.F. et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. data from the FLAME trial. Am. J. Respir. Crit. Care Med. 2017; 195 (9): 1189–1197. DOI:10.1164/rccm.201701-0193OC.; Ernst P., Saad N., Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur. Respir. J. 2015; 45 (2): 525–537. DOI:10.1183/09031936.00128914.; Kew K.M., Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; (3): CD010115. DOI:10.1002/14651858.CD010115.pub2.; Brode S.K., Campitelli M.A., Kwong J.C. et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur. Respir. J. 2017; 50 (3): pii 1700037. DOI:10.1183/13993003.00037-2017.; Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011; 66 (8): 699–708. DOI: 10. 1136/thx.2011.160028.; Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123 (11): 1001–1006. DOI:10.1016/j.amjmed.2010.06.019.; Horita N., Goto A., Shibata Y. et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst. Rev. 2017; (2): CD012066. DOI:10.1002/14651858.CD012066.pub2.; Yang I.A., Clarke M.S., Sim E.H., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (7): CD002991. DOI:10.1002/14651858.CD002991.pub3.; Weatherall M., Clay J., James K. et al. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009; 14 (7): 983–990. DOI:10.1111/j.1440-1843.2009.01589.x.; Uboweja A., Malhotra S., Pandhi P. Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis. Fundam. Clin. Pharmacol. 2006; 20 (3): 305–309. DOI:10.1111/j.1472-8206.2006.00397.x.; Huang K.W., Kuan Y.C., Chi N.F. et al. Chronic obstructive pulmonary disease is associated with increased recurrent peptic ulcer bleeding risk. Eur. J. Intern. Med. 2017; 37: 75–82. DOI:10.1016/j.ejim.2016.09.020.; Rossi A.P., Zanardi E., Zamboni M., Rossi A. Optimizing treatment of elderly COPD patients: what role for inhaled corticosteroids? Drugs Aging. 2015; 32 (9): 679–687. DOI:10.1007/s40266-015-0291-8.; van der Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166 (10): 1358–1363. DOI:10.1164/rccm.200206-512OC.; Choudhury A.B., Dawson C.M., Kilvington H.E. et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir. Res. 2007; 8: 93. DOI:10.1186/1465-9921-8-93.; Wouters E.F., Postma D.S., Fokkens B. et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005; 60 (6): 480–487. DOI:10.1136/thx.2004.034280.; Rossi A., Guerriero M., Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir. Res. 2014; 15: 77. DOI:10.1186/1465-9921-15-77.; Vogelmeier C., Worth H., Buhl R. et al. "Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 487–494. DOI:10.2147/COPD.S125616.; Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014; 371 (14): 1285–1294. DOI:10.1056/NEJMoa1407154.; Magnussen H., Tetzlaff K., Bateman E.D. et al. Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. Eur. Respir. J. 2016; 47 (2): 651–654. DOI:10.1183/13993003.01644-2015.; Watz H., Tetzlaff K., Wouters E.F. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 2016; 4 (5): 390–398. DOI:10.1016/S2213-2600(16)00100-4.; Vogelmeier C.F., Gaga M., Aalamian-Mattheis M. et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir. Res. 2017; 18 (1): 140. DOI:10.1186/s12931-017-0622-x.; Chapman K.R., Hurst J.R., Frent S.M. et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am. J. Respir. Crit. Care Med. 2018; 198 (3): 329–339. DOI:10.1164/rccm.201803-0405OC.; Frith P.A., Ashmawi S., Krishnamurthy S. et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial. Respirology. 2018; 23 (12): 1152–1159. DOI:10.1111/resp.13374.; Suissa S., Coulombe J., Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest. 2015; 148 (5): 1177–1183. DOI:10.1378/chest.15-0627.; Jarad N.A., Wedzicha J.A., Burge P.S., Calverley P.M. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir. Med. 1999; 93 (3): 161–166. DOI:10.1016/S0954-6111(99)90001-X.; Sulaiman I., Cushen B., Greene G. et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017; 195 (10): 1333–1343. DOI:10.1164/rccm.201604-0733OC.; Kardos P., Vogelmeier C., Worth H. et al. A two-year evaluation of the 'real life' impact of COPD on patients in Germany: The DACCORD observational study. Respir. Med. 2017; 124: 57–64. DOI:10.1016/j.rmed.2017.02.007. 58. Harlander M., Barrecheguren M., Turel M., Miravitlles M. Should patients switched from D to B in the GOLD 2017 classification be discontinued from inhaled corticosteroids? COPD. 2017; 14 (5): 465–468. DOI:10.1080/15412555.2017.1342233.; Авдеев С.Н., Айсанов З.Р., Белевский А.С. и др. Перспективы фармакотерапии хронической обструктивной болезни легких: возможности комбинированных бронходилататоров и место ингаляционных глюкокортикостероидов. Заключение Совета экспертов. Пуль монология. 2016; 26 (1): 65–72. DOI:10.18093/0869-0189- 2016-26-1-65-72.; Авдеев С.Н., Айсанов З.Р., Белевский А.С. и др. Новые возможности в профилактике обострений хронической обструктивной болезни легких. Заключение группы специалистов Российского респираторного общества. Пульмонология. 2017; 27 (1): 108–113. DOI: 10. 18093/0869-0189-2017-27-1-108-113.; Авдеев С.Н., Белевский А.С., Айсанов З.Р. и др. Возможности ингаляционной терапии по предупреждению обострений хронической обструктивной болезни легких. Заключение Совета экспертов Российского респираторного общества. Пульмонология. 2018; 28 (3): 368–380. DOI:10.18093/0869-0189-2018-28-3-368-380.; Crim C., Dransfield M.T., Bourbeau J. et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann. Am. Thorac. Soc. 2015; 12 (1): 27–34. DOI:10.1513/AnnalsATS.201409-413OC.; Matkovic Z., Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir. Med. 2013; 107 (1): 10–22. DOI:10.1016/j.rmed.2012.10.024.; Miravitlles M., Anzueto A. Antibiotic prophylaxis in COPD: why, when, and for whom? Pulm. Pharmacol Ther. 2015; 32: 119–123. DOI:10.1016/j.pupt.2014.05.002.; Izquierdo J.L., Cosio B.G. The dose of inhaled corticosteroids in patients with COPD: when less is better. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3539–3547. DOI:10.2147/COPD.S175047.; Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013; 68 (11): 1029–1036. DOI:10.1136/thoraxjnl-2012-202872.; Lipworth B., Kuo C.R., Jabbal S. Current appraisal of single inhaler triple therapy in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3003–3009. DOI:10.2147/COPD.S177333.; Janson C., Stratelis G., Miller-Larsson A. et al. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 3055–3064. DOI:10.2147/COPD.S143656.; https://journal.pulmonology.ru/pulm/article/view/1177

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/1177
https://doi.org/10.18093/0869-0189-2019-29-3-334-345

المؤلفون: S. N. Avdeev, A. S. Belevskiy, Z. R. Aisanov, V. V. Arkhipov, I. V. Leshchenko, S. I. Ovcharenko, A. I. Sinopal’nikov, A. A. Vizel’, A. V. Emel’yanov, A. V. Zhestkov, K. A. Zykov, N. A. Kuzubova, G. G. Prozorova, B. A. Chernyak, N. L. Shaporova, E. I. Shmelev, С. Н. Авдеев, А. C. Белевский, З. Р. Айсанов, В. В. Архипов, И. В. Лещенко, С. И. Овчаренко, А. И. Синопальников, А. А. Визель, А. В. Емельянов, А. В. Жестков, К. А. Зыков, Н. А. Кузубова, Г. Г. Прозорова, Б. А. Черняк, Н. Л. Шапорова, Е. И. Шмелев

المصدر: PULMONOLOGIYA; Том 28, № 3 (2018); 368-380 ; Пульмонология; Том 28, № 3 (2018); 368-380 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2018-28-3

مصطلحات موضوعية: тиотропий / олодатерол, exacerbations, prevention, inhalational therapy, long-acting bronchodilators, tiotropium, inhaled corticosteroids, tiotropium/olodaterol, обострения, профилактика, ингаляционные препараты, бронходилататоры длительного действия, тиотропий, ингаляционные глюкокортикостероиды

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/1007/844; GOLD 2018. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2018 Report. Available at: https://goldcopd.org [Accessed June 04, 2018].; Groenewegen K.H., Schols A.M., Wouters E.F. Mortality and mortality related factors after hospitalization for acute exacerbation of COPD. Chest. 2003; 124 (2): 459–467. DOI:10.1378/chest.124.2.459.; Buhl R., Criée C.P., Kardos P. et al. A year in the life of German patients with COPD: the DACCORD observational study. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 1639–1646. DOI:10.2147/COPD.S112110.; Arkhipov V., Arkhipova D., Miravitlles M. et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; (12): 3255–3262. DOI:10.2147/COPD.S142997.; Hurst J., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363 (12): 1128–1138. DOI:10.1056/NEJMoa0909883.; Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370 (9589): 786–796. DOI:10.1016/S0140-6736(07)61382-8.; Celli B.R., Barnes P.J. Exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29 (6): 1224–1238. DOI: 0.1183/09031936.00109906.; Seemungal T., Harper-Owen R., Bhowmik A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164 (9): 1618–1623. DOI:10.1164/ajrccm.164.9.2105011.; Vedel-Krogh S., Nielsen S.F., Lange P. et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am. J. Respir. Crit. Care Med. 2016; 193 (9): 965–974. DOI:10.1164/rccm.201509-1869OC.; Couillard S., Larivee P., Courteau J., Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017; 151 (2): 366–373. DOI:10.1016/j.chest.2016.10.003.; Miravitlles M., D’Urzo A., Singh D., Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir. Res. 2016; 17 (1): 112. DOI:10.1186/s12931-016-0425-5.; Miravitlles M., Calle M., Soler-Cataluña J.J. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch. Bronconeumol. 2012; 48 (3): 86–98. DOI:10.1016/j.arbres.2011.10.007.; Calverley P., Pauwels R., Löfdahl C.G. et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur. Respir. J. 2005; 26 (3): 406–413. DOI:10.1183/09031936.05.00143404.; Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469. DOI:10.1183/09031936.00099306.; Rennard S., Leidy N.K. Definition and severity of COPD exacerbations. In: Wedzicha W., Martinez F., eds. Exacerbations of Chronic Obstructive Pulmonary Disease (COPD). New York: Informa Healthcare; 2009.; Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363 (12): 1128–1138. DOI:10.1056/NEJMoa0909883.; Suissa S. Run-in bias in randomised trials: the case of COPD medications. Eur. Respir. J. 2017; 22; 49 (6): pii: 1700361. DOI:10.1183/13993003.00361-2017.; Halpin D.M., Kerkhof M., Soriano J.B. et al. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir. Res. 2016; 17 (1): 120. DOI:10.1186/s12931-016-0433-5.; Wedzicha J.A., Banerji D., Chapman K.R. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 0.1056/NEJMoa1516385.; Taskin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Eng. J. Med. 2008; 359 (15): 1543–1554. DOI:10.1056/NEJMoa0805800.; Bateman E.D., Tashkin D., Siafatas N. et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir. Med. 2010; 104 (10): 1460–1472. DOI:10.1016/j.rmed.2010.06.004.; Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus Salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103. DOI:10.1056/NEJMoa1008378.; Decramer L., Chapman J.R., Dahl R. et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir. Med. 2013; 1 (7): 524–533. DOI: 0.1016/S2213-2600(13)70158-9.; Chong J., Karner C., Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (9): CD009157. DOI:10.1002/14651858.CD009157.; Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26. DOI:10.1164/rccm.200707-973OC.; Powrie D.J., Wilkinson T.M.A., Donaldson G.C. et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur. Respir. J. 2007; 30 (3): 472–478. DOI:10.1183/09031936.00023907.; Horita N., Goto A., Shibata Y. et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst. Rev. 2017; (2): CD012066. DOI:10.1002/14651858.CD012066.; Rodrigo G., Price D., Anzueto A. et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; (12): 907–922. DOI:10.2147/COPD.S130482.; Zhong N., Wang C., Zhou X., et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; (10): 1015–1026. DOI:10.2147/COPD.S84436.; Wedzicha J.A., Decramer M., L. Ticker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med., 2013; 1 (3): 199–209. DOI:10.1016/S2213-2600(13)70052-3.; Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 2015; 45 (4): 969–979. DOI:10.1183/09031936.00136014.; Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494. DOI:10.1183/09031936.00200212.; Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med. 2014; 2 (6): 472–486. DOI:10.1016/S2213-2600(14)70065-7.; Martinez F.J., Rabe K.F., Ferguson G.T. et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017; 151 (2): 340–357. DOI:10.1016/j.chest.2016.11.028.; Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109 (10): 1312–1319. DOI:10.1016/j.rmed.2015.08.002.; Mahler D.A., Decramer M., D'Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43 (6): 1599–609. DOI:10.1183/09031936.00124013.; Beeh K.M., Westerman J., Kirsten A.M. et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharm. Ther. 2015; 32: 53–59. DOI:10.1016/j.pupt.2015.04.002.; Beeh K.M., Korn S., Beier J. et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study. Respir. Med. 2014; 108 (4): 584–592. DOI:10.1016/j.rmed.2014.01.006.; Calverley P.M.A., Anzueto A.R., Carter K. et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir. Med. 2018; 6 (5): 337–344. DOI:10.1016/S2213-2600(18)30102-4.; Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017; 27 (1): 13–20. DOI:10.18093/0869-0189-2017-27-1-13-20. / Aisanov Z.R., Avdeev S.N., Arkhipov V.V. et al. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Russian Pulmonology. 2017; 27 (1): 13–20. DOI:10.18093/0869-0189-2017-27-1-13-20 (in Russian).; Aisanov Z., Avdeev S., Arkhipov V. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 183–187. DOI:10.2147/COPD.S153770.; Washko G.R., Fan V.S., Ramsey S.D. et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 2008; 177 (2): 164–169. DOI:10.1164/rccm.200708-1194OC.; Beeh K.M., Burgel P.R., Franssen F.M.E. et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 2017; 196 (2): 139–149. DOI:10.1164/rccm.201609-1794CI.; Price D., Yawn B., Brusselle G., Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 2013; 22 (1): 92–100. DOI:10.4104/pcrj.2012.00092.; Ernst P., Saad N., Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur. Respir. J. 2015; 45 (2): 525–537. DOI:10.1183/09031936.00128914.; Kaplan A.G. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 2535–2548. DOI:10.2147/COPD.S93321.; Watz H., Tetzlaff K., Wouters E.F. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 2016; 4 (5): 390–398. DOI:10.1016/S2213-2600(16)00100-4.; Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014; 371 (14): 1285–1294. DOI:10.1056/NEJMoa1407154.; https://journal.pulmonology.ru/pulm/article/view/1007

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/1007
https://doi.org/10.18093/0869-0189-2018-28-3-368-380

المؤلفون: S. K. Zyryanov, I. N. D'yakov, С. К. Зырянов, И. Н. Дьяков

المصدر: PULMONOLOGIYA; Том 28, № 1 (2018); 61-68 ; Пульмонология; Том 28, № 1 (2018); 61-68 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2018-28-1

مصطلحات موضوعية: анализ влияния на бюджет, long-acting bronchodilators, indacaterol, tiotropium bromide, glycopyrronium bromide/indacaterol, economic burden, budget impact analysis on the, бронходилататоры длительного действия, длительно действующие β2-агонисты, длительно действующие М-холинолитические препараты, индакатерол, тиотропия бромид, гликопиррония бромид + индакатерол, клинико-экономическая оценка

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/962/805; Синопальников А.И., Зайцев А.А. Антибактериальная терапия обострений хронического бронхита / хронической обструктивной болезни легких. Ключевые положения. Медицинский совет. 2017; 18: 14–20. DOI:10.21518/2079-701X-2017-18-14-20.; Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65 (6): 473–479. DOI:10.1136/thx.2009.125435.; Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI:10.1056/NEJMoa1516385.; Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI:10.1016/S2213-2600(13)70052-3.; Frampton J.E. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74 (4): 465–488. DOI:10.1007/s40265-014-0194-8.; Banerji D., Fogel R., Patalano F. Indacaterol/glycopyrronium: a dual bronchodilator for COPD. Drug Discov. Today. 2018; 23 (1): 196–203. DOI:10.1016/j.drudis.2017.10.015.; Зырянов С.К., Фролов М.Ю., Белевский А.С. Клинико-экономическая эффективность применения фиксированной комбинации индакатерол / гликопиррония бромид при лечении хронической обструктивной болезни легких. Практическая пульмонология. 2016; (4): 76–84.; Donohue J. F., Betts K.A., Du E.X. et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Intern. J. COPD. 2017: 12: 367–381. DOI:10.2147/COPD.S119908.; Keininger D.L., Price D., Viswanad B. et al. Real-life experience of COPD patients on ease and accuracy of inhaler use: the REAL survey. J. Thorac. Dis. 2016; 8 (Suppl. 5): AB036. DOI:10.21037/jtd.2016.s036.; Molimard M., Raherison C., Lignot S. et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur. Respir. J. 2017; 49 (2): 1601794. DOI:10.1183/13993003.01794-2016.; https://journal.pulmonology.ru/pulm/article/view/962

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/962
https://doi.org/10.18093/0869-0189-2018-28-1-61-68

المؤلفون: Zyryanov S.K., D'yakov I.N.

المصدر: Pulmonologiya

مصطلحات موضوعية: Budget impact analysis, COPD, Economic burden, Glycopyrronium bromide/indacaterol, Indacaterol, Long-acting bronchodilators, Tiotropium bromide, хроническая обструктивная болезнь легких, бронходилататоры длительного действия, длительно действующие β2-агонисты, длительно действующие М-холинолитические препараты, индакатерол, тиотропия бромид, гликопиррония бромид + индакатерол, клинико-экономическая оценка, анализ влияния на бюджет

Relation: https://doi.org/10.18093/0869-0189-2018-28-1-61-68; https://repository.rudn.ru/records/article/record/7290/

الاتاحة: https://repository.rudn.ru/records/article/record/7290/